Skip to main content

Advertisement

SpringerLink
Log in

Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis

  • Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Aspirin-exacerbated diseases are important examples of drug hypersensitivities and include aspirin-exacerbated respiratory disease (AERD), aspirin- or non-steroidal anti-inflammatory drug (NSAID)-induced urticaria/angioedema, and aspirin- or NSAID-induced anaphylaxis. While each disease subtype may be distinguished by unique clinical features, the underlying mechanisms that contribute to these phenotypes are not fully understood. However, the inhibition of the cyclooxygenase-1 enzyme is thought to play a significant role. Additionally, eosinophils, mast cells, and their products, prostaglandins and leukotrienes, have been identified in the pathogenesis of AERD. Current diagnostic and treatment strategies for aspirin-exacerbated diseases remain limited, and continued research focusing on each of the unique hypersensitivity reactions to aspirin is essential. This will not only advance the understanding of these disease processes, but also lead to the subsequent development of novel therapeutics that patients who suffer from aspirin-induced reactions desperately need.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cahill KN et al. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(1):245–52. This is an original article demonstrating the role of PGD 2 in aspirin-induced rash and gastrointestinal symptoms in AERD. Additionally, it demonstrates the suppressive effect of high-dose aspirin therapy on PGD 2 and a connection with eosinophilia.

  2. Bochenek G et al. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol. 2014;133(1):98–103.e1-6.

    Article  CAS  PubMed  Google Scholar 

  3. Lee-Sarwar K et al. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;3(3):449–51.

    Article  Google Scholar 

  4. Swierczynska-Krepa M et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014;134(4):883–90.

    Article  CAS  PubMed  Google Scholar 

  5. Chen JR, Buchmiller BL, Khan DA. An hourly dose-escalation desensitization protocol for aspirin exacerbated respiratory disease. J Allergy Clin Immunol. 2015.

  6. Cardet JC. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol. 2014;2(2):208–13. The paper is an original research highlighting the frequency of alcohol-induced respiratory symptoms experienced by patients with AERD.

    Article  Google Scholar 

  7. Calais CJ, Banks TA. Resolution of alcohol-induced respiratory symptoms following aspirin desensitization in aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2015;114(5):429–30.

    Article  PubMed  Google Scholar 

  8. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015.

  9. Yip J, Yao CM, Lee JM. State of the art: a systematic review of the surgical management of aspirin exacerbated respiratory disease. Am J Rhinol Allergy. 2014;28(6):493–501.

    Article  PubMed  Google Scholar 

  10. Awad OG et al. Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? Laryngoscope. 2008;118(7):1282–6.

    Article  PubMed  Google Scholar 

  11. Mascia K et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116(5):970–5.

    Article  CAS  PubMed  Google Scholar 

  12. Morales DR et al. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015;70(7):828–35.

    Article  CAS  PubMed  Google Scholar 

  13. Bochenek G et al. Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease. Respir Med. 2015;109(5):588–95.

    Article  PubMed  Google Scholar 

  14. Dursun AB et al. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420–5.

    Article  PubMed  Google Scholar 

  15. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89(5):474–8.

    Article  PubMed  Google Scholar 

  16. Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133(1):286–7.e1-9.

  17. Makowska J, Lewandowska-Polak A, Kowalski ML. Hypersensitivity to aspirin and other NSAIDs: diagnostic approach in patients with chronic rhinosinusitis. Curr Allergy Asthma Rep. 2015;15(8):552.

    Article  Google Scholar 

  18. White AA, Bosso JV, Stevenson DD. The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2013;34(4):378–82.

    Article  CAS  PubMed  Google Scholar 

  19. Stevenson DD et al. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000;85(6 Pt 1):477–82.

    Article  CAS  PubMed  Google Scholar 

  20. Ta V, Simon R. State of the art: medical treatment of aspirin exacerbated respiratory disease (AERD). Am J Rhinol Allergy. 2015;29(1):41–3.

    Article  PubMed  Google Scholar 

  21. Peters AT et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113(4):347–85.

    Article  PubMed  Google Scholar 

  22. Humbert M et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol. 2014;2(5):525–36.e1.

  23. Gevaert P et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6.e1.

  24. Gevaert P et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95.e1-8.

  25. Klimek L et al. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? Curr Allergy Asthma Rep. 2014;14(6):441.

    Article  PubMed  Google Scholar 

  26. Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15(3):508.

    Article  PubMed  Google Scholar 

  27. Ibrahim C et al. A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma. Allergy Asthma Clin Immunol. 2014;10(1):64.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–6.

    Article  CAS  PubMed  Google Scholar 

  29. Havel M et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2013;270(2):571–8.

    Article  PubMed  Google Scholar 

  30. Cho KS et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575–81.

    Article  PubMed  Google Scholar 

  31. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119(1):157–64.

    Article  CAS  PubMed  Google Scholar 

  32. Comert S et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy. 2013;68(11):1443–51.

    Article  CAS  PubMed  Google Scholar 

  33. Fruth K et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68(5):659–65.

    Article  CAS  PubMed  Google Scholar 

  34. Rozsasi A et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228–34.

    Article  CAS  PubMed  Google Scholar 

  35. Howe R et al. Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease. World Allergy Organ J. 2014;7(1):18.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Sommer DD et al. Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. Otolaryngol Head Neck Surg. 2015;152(1):42–7.

    Article  PubMed  Google Scholar 

  37. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J. 1975;1(5949):67–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma. Naunyn Schmiedeberg's Arch Pharmacol. 1977;297 Suppl 1:S99–10.

    Article  Google Scholar 

  39. Szczeklik A et al. Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps. Pharmacol Res Commun. 1977;9(5):415–25.

    Article  CAS  PubMed  Google Scholar 

  40. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J. 1993;6(3):391–9.

    CAS  PubMed  Google Scholar 

  41. Mastalerz L et al. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. Allergy. 2014;69(11):1550–9.

    Article  CAS  PubMed  Google Scholar 

  42. Campo P et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy. 2013;68(8):1001–7.

    Article  CAS  PubMed  Google Scholar 

  43. Choi GS et al. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin Exp Allergy. 2013;43(7):730–40.

    Article  CAS  PubMed  Google Scholar 

  44. Steinke JW et al. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol. 2014;193(1):41–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Laidlaw TM et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790–8. The paper is an original research identifying elevated platelet-leukocyte aggregates in AERD and their role in cysteinyl leukotriene production.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Mitsui C et al. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015.

  47. Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(6):1407–14. This is a comprehensive review of our current understanding from human and mouse studies of the contribution of platelets to AERD.

    Article  CAS  PubMed  Google Scholar 

  48. Perez-Novo CA et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115(6):1189–96.

    Article  CAS  PubMed  Google Scholar 

  49. Steinke JW et al. Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2013;132(4):856–65.e1-3.

  50. Stevens WW et al. Cytokines in chronic rhinosinusitis: role in eosinophilia and aspirin exacerbated respiratory disease. Am J Respir Crit Care Med. 2015. Comprehensive original study characterizing and comparing the inflammatory mediators present in nasal polyps of CRSwNP and AERD.

  51. Aktas A, Kurt E, Gulbas Z. Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease. Inflammation. 2013;36(6):1553–9.

    Article  CAS  PubMed  Google Scholar 

  52. Aksu K et al. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2014;35(2):148–55.

    Article  CAS  PubMed  Google Scholar 

  53. Baba S et al. Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis. Clin Exp Allergy. 2014;44(5):701–12.

    Article  CAS  PubMed  Google Scholar 

  54. Hulse KE et al. Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression. J Allergy Clin Immunol. 2013;131(4):1075–83.

  55. Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2014;28(4):287–9.

    Article  PubMed  Google Scholar 

  56. Yoo HS et al. Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease. Int Arch Allergy Immunol. 2013;162(4):340–5.

    Article  CAS  PubMed  Google Scholar 

  57. Perez-Novo CA et al. Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship. Int Arch Allergy Immunol. 2004;133(3):255–60.

    Article  CAS  PubMed  Google Scholar 

  58. Lee JY et al. Role of staphylococcal superantigen-specific IgE antibodies in aspirin-intolerant asthma. Allergy Asthma Proc. 2006;27(5):341–6.

    Article  CAS  PubMed  Google Scholar 

  59. Park SM et al. Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways. Allergy Asthma Immunol Res. 2013;5(5):258–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Kurosawa M et al. Recent advance in investigation of gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease. Allergol Immunopathol. 2015;43(1):92–100.

    Article  CAS  Google Scholar 

  61. Kim SH et al. The SNP rs3128965 of HLA-DPB1 as a genetic marker of the AERD phenotype. PLoS One. 2014;9(12), e111220.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Chang HS et al. Association analysis of FABP1 gene polymorphisms with aspirin-exacerbated respiratory disease in asthma. Exp Lung Res. 2014;40(10):485–94.

    Article  CAS  PubMed  Google Scholar 

  63. Benninger MS, Holy CE. The impact of endoscopic sinus surgery on health care use in patients with respiratory comorbidities. Otolaryngol Head Neck Surg. 2014;151(3):508–15.

    Article  PubMed  Google Scholar 

  64. Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: a systematic review. Laryngoscope. 2015;125(7):1547–56.

    Article  PubMed  Google Scholar 

  65. Rajan JP et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–681 e1. This paper is a comprehensive meta-analysis providing the most current estimates of the prevalence of AERD among patients with asthma, CRS, or nasal polyps.

    Article  CAS  PubMed  Google Scholar 

  66. Townsend EA, Miller VM, Prakash YS. Sex differences and sex steroids in lung health and disease. Endocr Rev. 2012;33(1):1–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Jarjour NN et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185(4):356–62.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Stevens WW et al. A retrospective, cross-sectional study reveals that women with CRSwNP have more severe disease than men. Immun Inflammation Dis. 2015;3(1):14–22.

    Article  Google Scholar 

  69. Sanchez-Borges M et al. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2015;29(4):698–701. This study identified a subset of NSAID-exacerbated cutaneous disease patients in a population of chronic spontaneous urticaria patients (53/423) and found the patients with NSAID-exacerbated disease had longer duration of urticaria, more angioedema, and more atopy as compared to the NSAID-tolerant chronic spontaneous urticaria patients.

    Article  CAS  PubMed  Google Scholar 

  70. Mastalerz L, Setkowicz M, Szczeklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep. 2005;5(4):277–83.

    Article  CAS  PubMed  Google Scholar 

  71. Setkowicz M et al. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol. 2009;123(1):174–8.

    Article  CAS  PubMed  Google Scholar 

  72. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87(3):177–80.

    Article  CAS  PubMed  Google Scholar 

  73. Sanchez-Borges M et al. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol. 2009;19(5):375–82.

    CAS  PubMed  Google Scholar 

  74. Vidal C et al. Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 2013;132(4):989–91.

    Article  CAS  PubMed  Google Scholar 

  75. Picaud J et al. Anaphylaxis to diclofenac: nine cases reported to the Allergy Vigilance Network in France. Allergy. 2014;69(10):1420–3.

    Article  CAS  PubMed  Google Scholar 

  76. Quiralte J et al. Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies. Ann Allergy Asthma Immunol. 1997;78(3):293–6.

    Article  CAS  PubMed  Google Scholar 

  77. Woessner KM, Castells M. NSAID single-drug-induced reactions. Immunol Allergy Clin N Am. 2013;33(2):237–49.

    Article  Google Scholar 

  78. Simon RA. Prevention and treatment of reactions to NSAIDs. Clin Rev Allergy Immunol. 2003;24(2):189–98.

    Article  CAS  PubMed  Google Scholar 

  79. Kowalski ML et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–32.

    Article  CAS  PubMed  Google Scholar 

  80. Cahill KN, Laidlaw TM. Aspirin exacerbated respiratory disease: the search for a biomarker. Ann Allergy Asthma Immunol. 2014;113(5):500–1.

    Article  PubMed  Google Scholar 

  81. Palma-Carlos AG, Medina M, Palma-Carlos ML. Skin tests in NSAIDS hypersensitivity. Eur Ann Allergy Clin Immunol. 2006;38(6):182–5.

    CAS  PubMed  Google Scholar 

  82. Korosec P et al. Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance. Int Arch Allergy Immunol. 2011;155(3):257–62.

    Article  CAS  PubMed  Google Scholar 

  83. Bavbek S et al. Upregulation of CD63 or CD203c alone or in combination is not sensitive in the diagnosis of nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol. 2009;150(3):261–70.

    Article  CAS  PubMed  Google Scholar 

  84. Celik GE et al. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2009;39(10):1522–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Kim MS, Cho YJ. Flow cytometry-assisted basophil activation test as a safe diagnostic tool for aspirin/NSAID hypersensitivity. Allergy Asthma Immunol Res. 2012;4(3):137–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96(8):2751–3.

    Article  CAS  PubMed  Google Scholar 

  87. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

    Article  Google Scholar 

  88. Gaspoz JM et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346(23):1800–6.

    Article  PubMed  Google Scholar 

  89. Shaker M et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008;121(1):81–7.

    Article  CAS  PubMed  Google Scholar 

  90. Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol. 2013;110(2):92–5. This retrospective analysis of 9565 patients with coronary artery disease identified 142 patients (1.5 %) with listed aspirin allergy. Of the 142 patients, only 30 (21 %) had respiratory and/or cutaneous reactions, while the remaining patients had adverse effects attributable to aspirin.

    Article  CAS  PubMed  Google Scholar 

  91. Lanas A et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9(9):762–8.e6.

  92. Woessner KM. Aspirin desensitization for cardiovascular disease. Curr Opin Allergy Clin Immunol. 2015;15(4):314–22.

    Article  CAS  PubMed  Google Scholar 

  93. Rossini R et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008;101(6):786–9.

    Article  CAS  PubMed  Google Scholar 

  94. McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol. 2013;36(1):25–30.

    Article  PubMed  Google Scholar 

  95. Wong JT et al. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000;105(5):997–1001.

    Article  CAS  PubMed  Google Scholar 

  96. De Luca G et al. Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol. 2013;167(2):561–3.

    Article  PubMed  Google Scholar 

  97. White AA et al. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc. 2013;34(2):138–42.

    Article  CAS  PubMed  Google Scholar 

  98. Widal F, Abrami P, Lermoyez J. First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)--1922 (with a note on aspirin desensitization). J Asthma. 1987;24(5):297–300

Download references

Author information

Authors and Affiliations

  1. Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, 211 East Ontario Street, Suite 1000, Chicago, IL, 60611, USA

    Whitney Stevens

  2. Division of Rhematology, Immunology, and Allergy, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, 1 Jimmy Fund Way, Smith Building Room 638, Boston, MA, 02115, USA

    Kathleen Buchheit & Katherine N. Cahill

Authors
  1. Whitney Stevens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Buchheit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine N. Cahill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine N. Cahill.

Ethics declarations

Conflict of Interest

Drs. Stevens, Buchheit, and Cahill declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Anaphylaxis and Drug Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stevens, W., Buchheit, K. & Cahill, K.N. Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis. Curr Allergy Asthma Rep 15, 69 (2015). https://doi.org/10.1007/s11882-015-0569-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-015-0569-2

Keywords

Search

Navigation